MM-302 was designed to build on PEGylated liposomal doxorubicin (PLD) by retaining the improved cardiac safety profile of PLD relative to conventional doxorubicin and improving anti-tumor activity through immunotargeting of HER2. Here, ERBB2 is linked to neoplasm.